12-month health care costs and utilization, Lyme disease and control groups.

<p>*** statistically significant at p<.001 level,</p><p><sup>*</sup> Lyme disease sample includes only those persons with a test order and antibiotic treatment within 30 days of the test order, a diagnosis and antibiotic treatment within 30 days of the diagnosis, or a diagnosis, test order and antibiotic treatment within 30 days. The Lyme disease sample includes only those with 18 consecutive months of enrollment, including a 6-month “clean period” of enrollment prior to Lyme disease episode in which they were neither diagnosed with nor tested for Lyme disease.</p><p><sup>†</sup> Lyme disease and control samples are restricted to persons under 65 years of age, in commercial health insurance plans.</p><p><sup><b>‡</b></sup> Controls were matched to Lyme disease cases on age, sex, region, payer and enrollment year. Control group includes only those with 18 consecutive months of enrollment in a commercial health insurance plan. Control group was restricted to persons with outpatient costs greater than $0.</p><p><sup>§</sup> Medicine includes acupuncture, home health, home infusion and other special services, procedures and reports.</p><p><sup>||</sup> Adjusted impact calculations based on GLM regression analysis using the Huber/White sandwich estimator of variance and adjusting for year, region, age, and sex, and controlling for 44 high-cost conditions</p><p><sup>¶</sup> Adjusted ratio calculations for outpatient and emergency visits are based on negative binomial regression analysis using the Huber/White sandwich estimator of variance and adjusting for year, region, age, and sex, and controlling for 44 high-cost conditions.</p><p>12-month health care costs and utilization, Lyme disease and control groups.</p>